BioImagene meets with FDA officials to discuss pre-IDE submission of the diagnostic product version of its PATHIAM software.

Pune, India: Thursday, 20th October, 2005: BioImagene India Pvt. Ltd. a 100% subsidiary of BioImagene Inc. California (USA) launched its new premises at Godrej Eternia today. The official launch was done by Dr. R.A. Mashelkar, Director General, CSIR in the presence of Padmashree Lila Poonawalla, Advisory Board Member, BioImagene, and other industry veterans.

Since its inception in 2003, BioImagene has been completely on the growing curve. From 3 people, in the initial stages, it is now a strong team of 65 BIO-IT specialists. BioImagene today, is pioneering a new generation of life science Image Informatics solutions catering to the specific needs of research scientists and pathologists world over. In this short span, they have a prominent client portfolio, which reads almost like who’s who of the worlds top Pharma companies. Pharma giants like Eli Lilly, Pfizer, Merck, and Roche to name just a few as customers and research collaborations with prominent Universities, is a clear indication that they are a company, which is committed to Life Science research and development. BioImagene today has a strong IP portfolio too with 10 patents and 2 patent applications.

BioImagene is also working for esteemed customers like PHC Labs in Hong Kong, UC Davis at California, Bartes Hospital at UK, US Labs and Allergan LLC at Southern California to name a few.

Speaking of this occasion Dr. Mashelkar said, “BioImagene can become the provider of world-class solutions to the whole world in paramedics and diagnostics, solutions that will benefit both India and the World”. In the entire process of drug discovery, development, delivery, the key is that the drug should be affordable, available, and accessible to all, and what BioImagene is doing in this context is extraordinarily important. “We feel that bioinformatics is a tool for pharmaco-chemistry, and what you have added is a new tool to that armory. BioImagene is setting the world on fire”, Dr. Mashelkar further added.

Expressing his views Abhijeet Gholap, Co-founder and Managing Director, BioImagene India Pvt. Ltd. said, “Identifying and nurturing young scientists and IT specialists has been the key to our success. We understand and recognize that our people often represent the largest single area of investment.” Honing the technical skills of our employees by providing them with need and technology based training programs, and organizing soft skills sessions to maintain their high moral is also one of our key success factors. Working onsite alongside our clients gives our guys a better understanding of our customer perception to deliver well designed and well-thought productized solutions and services. Today I am proud and I am sure so are my people to be part of the BioImagene family, Abhijeet further added.

Working on the similar theme to support their business growth through customized solutions and services, to connect life science research with evolving IT, and take their innovations across nations, BioImagene is scaling up their software development infrastructure. The new state-of-the-art facility of over 6000 sq.ft. can house close to 100 IT Professionals. This development center provides 100% uninterrupted power supply, broadband internet connectivity, data storage and security, Smart card based access control system, world class hardware and software resources, IP based connectivity for voice communications and other such facilities.

Speaking at the launch an elated Mohan Uttarwar, Co-founder and CEO, BioImagene Inc said, “We are extremely happy to have the new facility of BioImagene launched at the hands of Dr. Mashelkar and Padmashree Lila Poonawalla. BioImagene is progressing tremendously, after the acquisition of Scimagix Inc, late last year, and plans to expand its offerings to all the major Pharma, CROs and biotech companies in the space of Tissue Image Analysis. With products TissueMine, Cellmine & Proteinmine we are well positioned for high throughput quantization during Drug Efficacy studies, Preclinical Studies and Animal ToxPath studies.”

Funded by prominent investors and led by a strong management team, BioImagene boasts of a stellar board of advisors consisting of experts from the medical, pathology and imaging technology fields. It has fostered close partnerships with some of the leading organizations in the academic, research and technology fields. In the future, partnerships are going to become even more important to BioImagene as it seeks companies to realize the full commercial value of its discovery and development potential. The company also intends to strengthen the IP portfolio by way of patents and research publications through its collaboration with Ohio State University, Columbus, Ohio